Kamikubo Yuichi, Neels Jaap G, Degryse Bernard
Department of Cell Biology, Division of Vascular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
Int J Biochem Cell Biol. 2009 Mar;41(3):578-85. doi: 10.1016/j.biocel.2008.07.006. Epub 2008 Jul 25.
We have previously reported that the serpin plasminogen activator inhibitor-1 activates the Janus kinase (Jak)/signal transducer and activator of transcription (Stat) signalling pathway and stimulates cell migration by binding to the low-density lipoprotein receptor-related protein. All the free forms (cleaved, latent or active) of this inhibitor were shown to be motogenic. However, the plasminogen activator inhibitor-1 can also interact with vitronectin which acts as a cofactor by increasing the half-life of the active form of the serpin. Since vitronectin influences most of the biological functions of the plasminogen activator inhibitor-1, we explored the effects of vitronectin on signalling and cell migration induced by this serpin. We found that the interaction between vitronectin and the plasminogen activator inhibitor-1 suppressed signalling and cell migration. In fact, a purified vitronectin(1-97)/plasminogen activator inhibitor-1 complex was not chemotactic. Vitronectin interaction with the plasminogen activator inhibitor-1 blocks the binding of this serpin to its motogenic receptor, the low-density lipoprotein receptor-related protein. Consequently, vitronectin inhibits the activation of the Janus kinase/signal transducer and activator of transcription signalling pathway by the plasminogen activator inhibitor-1 and subsequent cell migration. In conclusion, we have unveiled a new inhibitory role of vitronectin, which turns off the intracellular signalling and migration-promoting activity of the plasminogen activator inhibitor-1. Thus, the motogenic (cleaved, latent or active) and non-motogenic (in complex with vitronectin) forms of the plasminogen activator inhibitor-1 have different properties that may explain the rather contrasting physiological and pathological roles of this serpin.
我们之前曾报道,丝氨酸蛋白酶抑制剂纤溶酶原激活物抑制剂-1可激活Janus激酶(Jak)/信号转导子和转录激活子(Stat)信号通路,并通过与低密度脂蛋白受体相关蛋白结合来刺激细胞迁移。该抑制剂的所有游离形式(裂解型、潜伏型或活性型)均显示具有促迁移作用。然而,纤溶酶原激活物抑制剂-1也可与玻连蛋白相互作用,玻连蛋白作为一种辅因子,可延长丝氨酸蛋白酶抑制剂活性形式的半衰期。由于玻连蛋白影响纤溶酶原激活物抑制剂-1的大多数生物学功能,我们探究了玻连蛋白对该丝氨酸蛋白酶抑制剂诱导的信号传导和细胞迁移的影响。我们发现,玻连蛋白与纤溶酶原激活物抑制剂-1之间的相互作用会抑制信号传导和细胞迁移。事实上,纯化的玻连蛋白(1-97)/纤溶酶原激活物抑制剂-1复合物没有趋化活性。玻连蛋白与纤溶酶原激活物抑制剂-1的相互作用会阻止该丝氨酸蛋白酶抑制剂与其促迁移受体低密度脂蛋白受体相关蛋白的结合。因此,玻连蛋白可抑制纤溶酶原激活物抑制剂-1对Janus激酶/信号转导子和转录激活子信号通路的激活以及随后的细胞迁移。总之,我们揭示了玻连蛋白的一种新的抑制作用,即它可关闭纤溶酶原激活物抑制剂-1的细胞内信号传导和促进迁移的活性。因此,纤溶酶原激活物抑制剂-1的促迁移形式(裂解型、潜伏型或活性型)和非促迁移形式(与玻连蛋白形成复合物)具有不同特性,这可能解释了该丝氨酸蛋白酶抑制剂在生理和病理方面相当不同的作用。